NICE nixes Bristol's arthritis med for NHS use

Britain's healthcare cost watchdog NICE has recommended against using Bristol-Myers Squibb's (BMY.N) rheumatoid arthritis drug Orencia on the state health service as a second-line treatment. Report

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.